Ask AI
ESMO 2025 Breast Cancer

CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ESMO Congress

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

European Learners: 1.50 EBAC® CE Credit

Released: December 15, 2025

Expiration: June 14, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this text-based module, Cristina Saura, MD, PhD, and Paolo Tarantino, MD, PhD, summarize and review the clinical implications of key studies in breast cancer presented at the 2025 European Society for Medical Oncology Congress (ESMO). 

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

A 52-year-old postmenopausal woman presented with a 3.8 cm HER2-positive invasive ductal carcinoma (estrogen receptor [ER] 40%; progesterone receptor [PR] 10%) with clinically palpable axillary lymph nodes. She received 6 cycles of neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab and underwent breast-conserving surgery with axillary dissection. Final pathology revealed 1.2 cm of residual invasive disease in the breast and 3/12 positive nodes. 

Based on evidence presented at ESMO 2025 which of the following adjuvant treatment options would you recommend to improve her outcomes?

Which of the following findings was reported with a median follow-up of 6.3 years for adjuvant abemaciclib plus endocrine therapy (ET) vs ET alone in the phase III monarchE trial in patients with high-risk, hormone receptor (HR)–positive, HER2-negative early breast cancer?

A 56-year-old woman presents with newly diagnosed metastatic triple-negative breast cancer (TNBC). Testing reveals the tumor has a PD-L1 combined positive score <3 and no BRCA mutation. Her ECOG performance status is 0.

Based on the latest evidence presented at ESMO 2025, which of the following treatment options would be optimal as first-line therapy for this patient?